CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer
Open accessAbstract
CD39/CD73-adenosine pathway has been recently defined as an important tumor-induced immunosuppressive mechanism. We here documented a fraction of CD11b+CD33+ myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues from non-small cell lung cancer (NSCLC) patients expressed surface ectonucleotidases CD39 and CD73. Tumor TGF-β stimulated CD39 and CD73 expression, thereby inhibited T cell and NK cell activity, and protected tumor cells from the cytotoxic effect of chemotherapy through ectonucleotidase activity. Mechanistically, TGF-β triggered phosphorylation of mammalian target of rapamycin, and subsequently activated hypoxia-inducible factor-1α (HIF-1α) that induced CD39/CD73 expression on MDSCs. CD39 and CD73 on MDSCs, therefore, link their immunosuppressive and chemo-protective effects to NSCLC progression, providing novel targets for chemo-immunotherapeutic intervention.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Independent of glycolysis, HIFs induce immunosuppressive metabolites such as adenosine by transcriptionally activating ectoenzymes ENTPD2/CD39L1, CD39, and CD73, which convert extracellular ATP to adenosine, promoting MDSC maintenance and limiting immune checkpoint inhibitor activity.
“Independent of glycolysis, the HIFs can induce the production of immunosuppressive metabolites such as adenosine by transcriptionally activating ectoenzymes such as ENTPD2/CD39L1, CD39, and CD73 (Table 1), which contribute to the multistep conversion of extracellular ATP through ADP/AMP to adenosine, thus promoting the maintenance of MDSCs, which limits the activity of immune checkpoint inhibitors”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [91]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · see citing works
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D. J., Usheva, A., Erat, A., Chen, J., Enjyoji, K., Linden, J. M., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,478 · see citing works
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · see citing works
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,733 · see citing works
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works
Kuang, D., Zhao, Q., Peng, C., Xu, J., Zhang, J., Wu, C. Y., & Zheng, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 897 · see citing works
Zea, A. H., Rodrı́guez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D. F., Quiceno, D. G., Youmans, A. J., O’Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 852 · see citing works
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
Condamine, T., & Gabrilovich, D. I. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.10.002 · Cited by 846 · see citing works
Immune cell regulation by autocrine purinergic signalling
JUNGER, W. G. (2011) · Nature reviews. Immunology · doi:10.1038/nri2938 · Cited by 813 · see citing works
Purinergic Signaling during Inflammation
Eltzschig, H. K., Sitkovsky, M. V., & Robson, S. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1205750 · Cited by 716 · see citing works
Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 646 · see citing works
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 634 · see citing works
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
Rodrı́guez, P. C., Hernandez, C. P., Quiceno, D. G., Dubinett, S. M., Zabaleta, J., Ochoa, J. B., Gilbert, J., & Ochoa, A. C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050715 · Cited by 609 · see citing works
Purinergic Signaling during Inflammation
Eltzschig, H. K., Mv, S., & Robson, S. C. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300259 · Cited by 608 · see citing works
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 574 · see citing works
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
Stagg, J., Divisekera, U., McLaughlin, N. M., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 570 · see citing works
Caloric restriction mimetics enhance anticancer immunosurveillance
Pietrocola, F., Pol, J., Vacchelli, E., Rao, S., Enot, D. P., Baracco, E. E., Levesque, S., Castoldi, F., Jacquelot, N., Yamazaki, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.016 · Cited by 542 · see citing works
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Loi, S., Pommey, S., Haibe‐Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 497 · see citing works
Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma
Ochoa, A. C., Zea, A. H., Hernandez, C., & Rodrı́guez, P. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2197 · Cited by 489 · see citing works
Obermajer, N., Muthuswamy, R., Odunsi, K. O., Edwards, R. P., & Kaliński, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2449 · Cited by 465 · see citing works
Jin, D., Fan, J., Wang, L., Thompson, L. F., Liu, A., Daniel, B. J., Shin, T., Curiel, T. J., & Zhang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3109 · Cited by 433 · see citing works
Self-citationCui, T. X., Kryczek, I., Zhao, L., Zhao, E., Kuick, R. D., Roh, M. H., Vatan, L., Szeliga, W., Mao, Y., Thomas, D. G., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.025 · Cited by 426 · see citing works
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
Stagg, J., Divisekera, U., Duret, H., Sparwasser, T. D., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401 · see citing works
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 383 · see citing works
Poschke, I. C., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 381 · see citing works
Liu, X., Sun, Y., Constantinescu, S. N., Karam, E., Weinberg, R. A., & Lodish, H. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10669 · Cited by 356 · see citing works
Chalmin, F., Mignot, G., Bruchard, M., Chevriaux, A., Végran, F., Hichami, A., Ladoire, S., Derangère, V., Vincent, J., Masson, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.019 · Cited by 338 · see citing works
Metabolic Reprogramming of Cancer-Associated Fibroblasts by IDH3α Downregulation
Zhang, D., Wang, Y., Shi, Z., Liu, J., Sun, P., Hou, X., Zhang, J., Zhao, S., Zhou, B. P., & Mi, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.006 · Cited by 334 · see citing works
Self-citationLiu, C., Wang, Y., Wang, C.-L., Feng, P., Ko, H., Liu, Y., Wu, Y., Chu, Y., Chung, F., Kuo, C.-H. S., et al. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0634-0 · Cited by 312 · see citing works
Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Müller, C. E., Murakami, T., & Robson, S. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.007 · Cited by 279 · see citing works
Zhang, B., Wang, Z., Wu, L., Zhang, M., Li, W., Ding, J., Zhu, J., Wei, H., & Zhao, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057114 · Cited by 273 · see citing works
Self-citationCD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., & Zhang, B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45559 · Cited by 262 · see citing works
Self-citationAdenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
Ryzhov, S. V., Novitskiy, S. V., Goldstein, A. E., Biktasova, A., Blackburn, M. R., Biaggioni, I., Dikov, M. M., & Feoktistov, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101225 · Cited by 261 · see citing works
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
Filipazzi, P., Huber, V., & Rivoltini, L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1161-9 · Cited by 244 · see citing works
Bastid, J., Regairaz, A., Bonnefoy, N., Déjou, C., Giustiniani, J., Laheurte, C., Cochaud, S., Laprévotte, E., Funck‐Brentano, E., Hémon, P., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0018 · Cited by 241 · see citing works
CD73: A Novel Target for Cancer Immunotherapy
Zhang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1544 · Cited by 234 · see citing works
Self-citationHuang, A., Zhang, B., Wang, B., Zhang, F., Fan, K., & Guo, Y. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1450-6 · Cited by 209 · see citing works
Self-citationENTPD1/CD39 is a promising therapeutic target in oncology
Bastid, J., Regairaz, A., Alberici, G. F., Bonnefoy, N., Eliaou, J.-F., & Bensussan, A. (2012) · Oncogene · doi:10.1038/onc.2012.269 · Cited by 202 · see citing works
Häusler, S. F., del Barrio, I. M., Strohschein, J., Chandran, P. A., Engel, J. B., Hönig, A., Ossadnik, M., Horn, E., Fischer, B., Krockenberger, M., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1040-4 · Cited by 193 · see citing works
High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
Wu, X., He, X., Chen, Y., Yuan, R., Zeng, Y., Lian, L., Zou, Y., Lan, N., Wu, X., & Lan, P. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23056 · Cited by 179 · see citing works
Feng, P., Lee, K., Chang, Y.-L., Chan, Y., Kuo, L.-W., Lin, T., Chung, F., Kuo, C.-S., Yu, C.-T., Lin, S., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0636oc · Cited by 168 · see citing works
Li, J.-Y., Duan, X.-F., Wang, L.-P., Xu, Y.-J., Huang, L., Zhang, T.-F., Liu, J.-Y., Li, F., Zhang, Z., Yue, D.-L., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/286170 · Cited by 157 · see citing works
Self-citationIannone, R., Miele, L., Maiolino, P., Pinto, A., & Morello, S. (2013) · Neoplasia · doi:10.1593/neo.131748 · Cited by 152 · see citing works
Improving cancer immunotherapy by targeting tumor-induced immune suppression
Stewart, T. J., & Smyth, M. J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9280-5 · Cited by 152 · see citing works
Altered purinergic signaling in CD73‐deficient mice inhibits tumor progression
Yegutkin, G. G., Marttila‐Ichihara, F., Karikoski, M., Niemelä, J., Laurila, J. P., Elima, K., Jalkanen, S., & Salmi, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201041292 · Cited by 150 · see citing works
Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma
Lu, X.-X. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i12.1912 · Cited by 120 · see citing works
Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors
Ryzhov, S. V., Pickup, M. W., Chytil, A. M., Gorska, A. E., Zhang, Q., Owens, P., Feoktistov, I., Moses, H. L., & Novitskiy, S. V. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400578 · Cited by 118 · see citing works
Schuler, P. J., Schilling, B., Harasymczuk, M., Hoffmann, T. K., Johnson, J. T., Lang, S., & Whiteside, T. L. (2012) · European Journal of Immunology · doi:10.1002/eji.201142347 · Cited by 111 · see citing works
CD73 promotes tumor growth and metastasis
Zhang, B. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18068 · Cited by 104 · see citing works
Self-citationDefective Antitumor Function of Monocyte-Derived Macrophages from Epithelial Ovarian Cancer Patients
Gordon, I. O., & Freedman, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2254 · Cited by 86 · see citing works
Extracellular adenosine metabolism in immune cells in melanoma
Umansky, V., Shevchenko, I., Bazhin, A. V., & Utikal, J. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1553-8 · Cited by 68 · see citing works
Rozen‐Zvi, B., Hayashida, T., Hubchak, S. C., Hanna, C., Platanias, L. C., & Schnaper, H. W. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00215.2013 · Cited by 68 · see citing works
Ugurel, S., Uhlig, D., Pf�hler, C., Tilgen, W., Schadendorf, D., & Reinhold, U. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0489-1 · Cited by 52 · see citing works
Perry, C., Hazan‐Halevy, I., Kay, S., Cipok, M., Grisaru, D., Deutsch, V. R., Polliack, A., Naparstek, E., & Herishanu, Y. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1425-2 · Cited by 50 · see citing works
Yue, D., Zhang, Z., Li, J., Chen, X., Yü, P., Liu, S., Shi, X., Li, L., Wang, L., Huang, L. J., et al. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.06.007 · Cited by 46 · see citing works
Self-citationDas, F., Ghosh‐Choudhury, N., Bera, A., Dey, N., Abboud, H. E., Kasinath, B. S., & Choudhury, G. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.455782 · Cited by 33 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,907 · see citing works
Self-citationHypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612 · see citing works
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y.-S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 914 · see citing works
Self-citationImmunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 846 · see citing works
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Virgilio, F. D., Sarti, A. C., Falzoni, S., Marchi, E. D., & Adinolfi, E. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 730 · see citing works
Metabolic Regulation of Macrophage Polarization in Cancer
Mehla, K., & Singh, P. K. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.10.007 · Cited by 622 · see citing works
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 601 · see citing works
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 546 · see citing works
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S., Kurt, F. G. Ö., Arkhypov, I., Utikal, J. S., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 514 · see citing works
Fates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459 · see citing works
Self-citationMyeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455 · see citing works
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Viganó, S., Alatzoglou, D., Irving, M. B., Ménétrier‐Caux, C., Caux, C., Romero, P. J., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 422 · see citing works
Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
Chen, D., Zhang, X., Li, Z., & Zhu, B. (2021) · Theranostics · doi:10.7150/thno.51777 · Cited by 390 · see citing works
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385 · see citing works
“Moreover, TGF-β stimulates CD39 and CD73 expression, thereby inhibiting autologous CD8+ T cell proliferation and function (Li et al., 2017).”
BackgroundSelf-citationReactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression
Ohl, K., & Tenbrock, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02499 · Cited by 335 · see citing works
Cicco, P. D., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 338 · see citing works
Moesta, A. K., Li, X.-Y., & Smyth, M. J. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0376-4 · Cited by 324 · see citing works
Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer
Bao, M. H.-R., & Wong, C. C.-L. (2021) · Cells · doi:10.3390/cells10071715 · Cited by 316 · see citing works
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 310 · see citing works
Yang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 294 · see citing works
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
Wang, Y., Ding, Y., Guo, N., & Wang, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00172 · Cited by 282 · see citing works
The role of hypoxia‐inducible factor 1 in tumor immune evasion
Li, Y., Wu, W., Wang, X., Fang, L., Adam, V., Nepovimová, E., Wu, Q., & Kuča, K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21771 · Cited by 268 · see citing works
Self-citationLi, L., Wang, L., Li, J., Fan, Z., Li, Y., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 266 · see citing works
Self-citationTGF-β signaling in the tumor metabolic microenvironment and targeted therapies
Shi, X., Yang, J., Deng, S., Xu, H., Wu, D., Zeng, Q., Wang, S., Hu, T., Wu, F., & Zhou, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01349-6 · Cited by 262 · see citing works
Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R. M. R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 265 · see citing works
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Stultz, J., & Fong, L. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00340-5 · Cited by 242 · see citing works
Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells
Ni, C., Fang, Q.-Q., Chen, W., Jiang, J.-X., Zhou, J., Ye, J., Zhang, T., Yang, L., Meng, F.-B., Xia, W.-J., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0129-7 · Cited by 240 · see citing works
Self-citationATP and cancer immunosurveillance
Kepp, O., Bezu, L., Yamazaki, T., Virgilio, F. D., Smyth, M. J., Kroemer, G., & Galluzzi, L. (2021) · The EMBO Journal · doi:10.15252/embj.2021108130 · Cited by 231 · see citing works
mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment
Mafi, S., Mansoori, B., Taeb, S., Sadeghi, H., Abbasi, R., Cho, W. C. S., & Rostamzadeh, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774103 · Cited by 225 · see citing works
The role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 228 · see citing works
Gao, Q., Wang, S., Chen, X., Cheng, S., Zhang, Z., Li, F., Huang, L. J., Yang, Y., Zhou, B., Yue, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0511-6 · Cited by 216 · see citing works
Self-citationHypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 207 · see citing works
NK cells and solid tumors: therapeutic potential and persisting obstacles
Tong, L., Jiménez‐Cortegana, C., Tay, A. H. M., Wickström, S. L., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 193 · see citing works
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Liu, Z., Zhou, Z., Dang, Q., Xu, H. M., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 198 · see citing works
Self-citationMyeloid-derived suppressor cells—new and exciting players in lung cancer
Yang, Z., Guo, J., Weng, L., Tang, W., Jin, S., & Ma, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-0843-1 · Cited by 191 · see citing works
ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain
Yegutkin, G. G., & Boison, D. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000528 · Cited by 171 · see citing works
Targeting CD73 to augment cancer immunotherapy
Roh, M., Wainwright, D. A., Wu, J. D., Wan, Y., & Zhang, B. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.001 · Cited by 166 · see citing works
Self-citationTargeting the CD73-adenosine axis in immuno-oncology
Allard, D., Chrobák, P., Allard, B., Messaoudi, N., & Stagg, J. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.05.001 · Cited by 161 · see citing works
Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment
Zhang, H., Li, S., Wang, D., Liu, S. M., Xiao, T., Gu, W., Yang, H., Wang, H. Z., Yang, M., & Chen, P. (2024) · Biomarker Research · doi:10.1186/s40364-024-00646-1 · Cited by 169 · see citing works
Antuamwine, B. B., Bosnjakovic, R., Hofmann-Vega, F., Wang, X., Θεοδοσίου, Θ., Iliopoulos, I., & Brandau, S. (2022) · Immunological Reviews · doi:10.1111/imr.13176 · Cited by 159 · see citing works
Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications
Shi, R., Liao, C., & Zhang, Q. H. (2021) · Cells · doi:10.3390/cells10030678 · Cited by 148 · see citing works
Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity
Xue, V., Chung, J., Córdoba, C. G., Cheung, A., Kang, W., Lam, E., Leung, K., To, K. F., Lan, H., & Tang, P. (2020) · Cancers · doi:10.3390/cancers12113099 · Cited by 131 · see citing works
Cd73: An Emerging Checkpoint for Cancer Immunotherapy
Chen, S., Wainwright, D. A., Wu, J. D., Wan, Y., Matei, D. E., Zhang, Y., & Zhang, B. (2019) · Immunotherapy · doi:10.2217/imt-2018-0200 · Cited by 145 · see citing works
Self-citationOn the mechanism of anti-CD39 immune checkpoint therapy
Allard, D., Allard, B., & Stagg, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000186 · Cited by 132 · see citing works
Role of mTOR Signaling in Tumor Microenvironment: An Overview
Conciatori, F., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., Milella, M., & Ciuffreda, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082453 · Cited by 129 · see citing works
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
Augustin, R. C., Leone, R. D., Naing, A., Fong, L. H., Bao, R., & Luke, J. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004089 · Cited by 127 · see citing works
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01795-9 · Cited by 122 · see citing works
Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function
Fernández, J. P., Luddy, K. A., Harmon, C., & O’Farrelly, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174131 · Cited by 119 · see citing works
Yu, Q., Xia, Y., Lin, Z., Qu, Y., Qi, Y., Chen, Y., Zhou, Q., Zeng, H., Wang, J., Chang, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02563-2 · Cited by 118 · see citing works
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Consonni, F. M., Porta, C., Marino, A., Pandolfo, C., Mola, S., Bleve, A., & Sica, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00949 · Cited by 110 · see citing works
Kurt, F. G. Ö., Lasser, S., Arkhypov, I., Utikal, J. S., & Umansky, V. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170762 · Cited by 109 · see citing works
Targeting myeloid-derived suppressor cells for cancer immunotherapy
Liu, Y., Wei, G., Cheng, W. A., Dong, Z., Sun, H., Lee, V. Y., Cha, S.-C., Smith, D. L., Kwak, L. W., & Qin, H. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2175-3 · Cited by 107 · see citing works
Hasan, M. M., Thompson-Snipes, L., Klintmalm, G. B. G., Demetris, A. J., O’Leary, J. G., Oh, S., & Joo, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900488 · Cited by 107 · see citing works
Tomić, S., Joksimović, B., Bekić, M., Vasiljević, M., Milanović, M., Čolić, M. J., & Vučević, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00475 · Cited by 103 · see citing works
The impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 100 · see citing works
Chen, S., Fan, J., Zhang, M., Qin, L., Dominguez, D., Long, A., Wang, G., Ma, R., Li, H., Zhang, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08123-8 · Cited by 98 · see citing works
Self-citationChambers, A. M., & Matosevic, S. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00060 · Cited by 95 · see citing works
Purinergic Signaling in the Hallmarks of Cancer
Campos‐Contreras, A. D. R., Díaz‐Muñoz, M., & Vázquez‐Cuevas, F. G. (2020) · Cells · doi:10.3390/cells9071612 · Cited by 94 · see citing works
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Hao, Z., Li, R., Wang, Y., Li, S., Hong, Z., & Han, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00333-5 · Cited by 94 · see citing works
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Valeri, A., García-Ortiz, A., Castellano, E., Córdoba, L., Maroto-Martín, E., Encinas, J., Leivas, A., Rı́o, P., & Martínez‐López, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953849 · Cited by 94 · see citing works
Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis
Qin, G., Lian, J., Huang, L. J., Zhao, Q., Liu, S., Zhang, Z., Chen, X., Yue, D., Li, L., Li, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442167 · Cited by 94 · see citing works
Self-citationTargeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
de Leve, S., Wirsdörfer, F., & Jendrossek, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00698 · Cited by 93 · see citing works
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Ziogas, D. C., Theocharopoulos, C., Lialios, P., Foteinou, D., Koumprentziotis, I., Xynos, G., & Gogas, H. J. (2023) · Cancers · doi:10.3390/cancers15102718 · Cited by 92 · see citing works
Liu, C.-M., Yang, L., Xu, H.-Y., Zheng, S.-F., Wang, Z.-Y., Wang, S., Yang, Y.-N., Zhang, S.-Y., Feng, X., Sun, N., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02356-7 · Cited by 85 · see citing works
Self-citationLarge-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma
Zhang, C., Zhang, Z., Li, F., Shen, Z., Qiao, Y., Li, L., Liu, S., Song, M., Zhao, X., Ren, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1461304 · Cited by 90 · see citing works
Self-citationCanonical and non-canonical adenosinergic pathways
Ferretti, E., Horenstein, A. L., Canzonetta, C., Costa, F., & Morandi, F. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.03.007 · Cited by 89 · see citing works
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Harvey, J. B., Phan, L. H., Villarreal, O. E., & Bowser, J. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00508 · Cited by 87 · see citing works
Targeting purine metabolism in ovarian cancer
Liu, J., Hong, S., Jiang, Y., Zhang, X., Wang, Y., Wang, H., Peng, J., & Hong, L. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-01022-z · Cited by 87 · see citing works
Hsu, S., Cheng, K., Mgbeahuruike, M. O., Lin, Y., Wu, C., Wang, H., Yen, C., Chiu, C., & Sheu, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179453 · Cited by 83 · see citing works
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
Tumino, N., Pace, A. L. D., Besi, F., Quatrini, L., Vacca, P., & Moretta, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638841 · Cited by 84 · see citing works
Implication of TIGIT+ human memory B cells in immune regulation
Hasan, M. M., Nair, S. S., O’Leary, J. G., Thompson-Snipes, L., Nyarige, V., Wang, J., Park, W. D., Stegall, M. D., Heilman, R. L., Klintmalm, G. B. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21413-y · Cited by 82 · see citing works
Wu, L., Xie, W., Li, Y., Ni, Q., Timashev, P. S., Lyu, M., Xia, L., Zhang, Y., Liu, L., Yuan, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202105376 · Cited by 82 · see citing works
Self-citationThe Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis
Mallikarjuna, P., Zhou, Y., & Landström, M. (2022) · Biomolecules · doi:10.3390/biom12050635 · Cited by 82 · see citing works
Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy
Arab, S., & Hadjati, J. (2019) · Immune Network · doi:10.4110/in.2019.19.e23 · Cited by 80 · see citing works
Immunotherapy of targeting MDSCs in tumor microenvironment
Sui, H., Dongye, S., Liu, X., Xu, X., Wang, L., Jin, C. Q., Yao, M., Gong, Z., Jiang, D., Zhang, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.990463 · Cited by 80 · see citing works
Self-citationMDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
Vanhaver, C., van der Bruggen, P., & Bruger, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132872 · Cited by 76 · see citing works
Adenosine in cancer immunotherapy: Taking off on a new plane
Zhang, C., Wang, K., & Wang, H. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189005 · Cited by 79 · see citing works
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
Bao, X., & Xie, L. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02430-1 · Cited by 74 · see citing works
Autoimmunity and Cancer—Two Sides of the Same Coin
Sakowska, J., Arcimowicz, Ł., Jankowiak, M., Papak, I., Markiewicz, A., Dziubek, K., Kurkowiak, M., Kote, S., Kaźmierczak-Siedlecka, K., Połom, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.793234 · Cited by 73 · see citing works
The Engagement Between MDSCs and Metastases: Partners in Crime
Trovato, R., Canè, S., Petrova, V., Sartoris, S., Ugel, S., & Sanctis, F. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00165 · Cited by 71 · see citing works
The elegant complexity of mammalian ecto-5′-nucleotidase (CD73)
Alcedo, K. P., Bowser, J. L., & Snider, N. T. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.05.008 · Cited by 70 · see citing works
Giatromanolaki, A. N., Kouroupi, M., Pouliliou, S., Mitrakas, A. G., Hasan, F., Pappa, A., & Koukourakis, M. I. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118389 · Cited by 71 · see citing works
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 70 · see citing works
Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer
Wang, Y., Jia, A., Bi, Y., Wang, Y., & Liu, G. (2020) · Cells · doi:10.3390/cells9041011 · Cited by 70 · see citing works
Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease
Horst, A. K., Kumashie, K. G., Neumann, K., Diehl, L., & Tiegs, G. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00568-6 · Cited by 71 · see citing works
The Clinical Significance of CD73 in Cancer
Bach, N., Winzer, R., Tolosa, E., Fiedler, W., & Brauneck, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411759 · Cited by 71 · see citing works
Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
Zhou, Y., Yuan, J. T., Xu, K., Li, S., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c11260 · Cited by 73 · see citing works
TGF-β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment
Angioni, R., Sánchez‐Rodríguez, R., Viola, A., & Molon, B. (2021) · Cancers · doi:10.3390/cancers13030401 · Cited by 68 · see citing works
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 65 · see citing works
Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints
Baghbani, E., Noorolyai, S., Shanehbandi, D., Mokhtarzadeh, A., Maleki, L. A., Khaze, V., Brunetti, O., Rahmani, S., Shadbad, M. A., Baghbanzadeh, A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119826 · Cited by 62 · see citing works
Lakshmanachetty, S., Cruz, J. C., Hoffmeyer, E., Cole, A. P., & Mitra, S. S. (2021) · Cells · doi:10.3390/cells10040893 · Cited by 62 · see citing works
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 59 · see citing works
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Kashyap, A. S., Thelemann, T., Klar, R., Kallert, S. M., Festag, J., Buchi, M., Hinterwimmer, L., Schell, M., Michel, S., Jaschinski, F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0545-9 · Cited by 60 · see citing works
OXPHOS inhibitors, metabolism and targeted therapies in cancer
Cadassou, O., & Jordheim, L. P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115531 · Cited by 59 · see citing works
Review immune response of targeting CD39 in cancer
Liu, Y., Li, Z., Zhao, X., Xiao, J., Bi, J., Li, X.-Y., Chen, G., & Lu, L. (2023) · Biomarker Research · doi:10.1186/s40364-023-00500-w · Cited by 59 · see citing works
Self-citationCD39 – A bright target for cancer immunotherapy
Guo, S., Han, F., & Zhu, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113066 · Cited by 57 · see citing works
Tumino, N., Besi, F., Martini, S., Pace, A. L. D., Munari, E., Quatrini, L., Pelosi, A., Fiore, P. F., Fiscon, G., Paci, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803014 · Cited by 57 · see citing works
Pfefferle, A., Jacobs, B., Netskar, H., Ask, E. H., Lorenz, S., Clancy, T., Goodridge, J. P., Sohlberg, E., & Malmberg, K. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.058 · Cited by 56 · see citing works
Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion
Shao, X., Hua, S., Feng, T., Ocansey, D. K. W., & Yin, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911789 · Cited by 57 · see citing works
The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
Jiang, X., Wu, X., Xiao, Y., Wang, P., Zheng, J., Wu, X., & Jin, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1110325 · Cited by 55 · see citing works
- Authors
- Li, J., Wang, L., Chen, X., Li, L., Li, Y., Ping, Y., Huang, L., Yue, D., Zhang, Z., Wang, F., Li, F., Yang, L., Huang, J., Yang, S., Li, H., Zhao, X., Dong, W., Yan, Y., Zhao, S., Huang, B., Zhang, B., & Zhang, Y.
- Affiliations
- First Affiliated Hospital of Zhengzhou University (CN)
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Northwestern University (US)
- Corresponding author
- Wang, Liping
- Zhang, Bin
- Zhang, Yi
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-05-30
- Volume
- 6
- Issue
- 6
- Pages
- e1320011-e1320011
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5486179
- OpenAlex
- W2605835842
- Cited by
- 299
- References
- 57
- Citations by year
- 2026: 22 · 2025: 32 · 2024: 33 · 2023: 33 · 2022: 52 · 2021: 45 · 2020: 37 · 2019: 26 · 2018: 19
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81171985, 112300410153, 122300410155, 81171986, 20110110001)
- Science and Technology Department of Henan Province
- National Institutes of Health (CA149669)
- National Cancer Institute (R01CA208354)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- CD39/CD73, myeloid-derived suppressor cells, non-small cell lung cancer, TGF-beta, mTOR, HIF-1α, adenosine pathway, ectonucleotidases, tumor immunosuppression, chemoresistance, T cell suppression, NK cell inhibition, chemoimmunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
